Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Pliant Therapeutics, Inc.

< Previous 1 2 Next >
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics to Participate in Upcoming Investor Conferences
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics to Participate in Upcoming Investor Conferences
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics to Participate in Upcoming Investor Conferences
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
Pliant Therapeutics to Participate in Upcoming Investor Conferences
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Tickers PLRX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.